GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations
A German court temporarily suspended proceedings in CureVac's IP lawsuit against BioNTech.
The cold and flu season is upon us, but COVID-19 cases and hospitalizations have also increased recently. The Centers for Disease Control (CDC) will be voting
The company, which focuses on mRNA therapies, began a phase 1 trial for its cancer vaccine candidate.
The war on cancer advances with the German company's latest clinical development.
March S&P 500 futures (ESH23) are trending down -0.41% this morning after three major U.S. benchmark indices ended the regular session lower as weak economic data and hawkish comments from Federal Reserve...
The stock rose for the third consecutive day.
Unsurprisingly, positive sentiment toward Novavax’s change of leadership bolstered unusual options activity for NVAX stock. Still, prospective investors need to tread very carefully.
With CureVac recently announcing early positive results for its mRNA-based seasonal flu and COVID-19 vaccine, CVAC stock enjoyed some much-needed relevance.
March S&P 500 futures (ESH23) are trending up +0.40% this morning after three major U.S. benchmark indices closed sharply higher on Friday after a crucial U.S. jobs report pointed to cooling wage growth...